138 found that CR led to an average of 55% less tumor development in CR-fed mice than in ad libitum controls
When looking at the percentage of participants that dropped out of the trial due to adverse effects, 2-6% of patients in the cagrilintide group discontinued treatment early while 7% of the participants receiving liraglutide discontinued treatment early, These findings were in comparison to only 3% of test subjects from the placebo group that discontinued treatment due to adverse events [1]
In APP/PS1 Alzheimer's mice, Dihexa treatment not only prevented cognitive decline but actively restored spatial learning abilities that had already been compromised, indicating the compound promotes recovery of function in damaged neural circuits
Source: Research Gate In summary, larazotide and BPC 157 both help to regulate intestinal barrier function and thus act as the first line of defense against inflammation by preventing injury in the first place
Injectable GHK-Cu bypasses the skin barrier entirely, delivering the compound systemically rather than locally
Compounds circulating online or through private clinics without this authorisation fall outside the regulatory framework designed to protect patient safety